Qualification and Implementation of an Ultraviolet Autonomous Robot for Use in Pharmaceutical Clean Rooms
AstraZeneca has qualified an autonomous UV C disinfection robot for GMP pharmaceutical clean rooms, delivering evidence-based, chemical-free surface decontamination. Using a rigorous programme aligned to EN 13697 and USP <1072>, we established organism specific death curves across representative cleanroom surfaces and global environmental isolates. The robot achieves a ≥3 log reduction for vegetative organisms at 100 mJ/cm² and enables dose escalation to ≥200 mJ/cm² for Bacillus spores and ≥500 mJ/cm² for resilient moulds. The robot was also qualified versus degradation risks for common cleanroom surfaces to limit particle issues. This innovation advances manufacturing compliance through digital, automated, and standardised disinfection, reduces chemical burden, and strengthens global reproducibility and compliance.
The Problem Statement
Pharmaceutical clean rooms require consistent, validated bioburden control. Current approaches rely heavily on manual chemical disinfection, which presents challenges:
• Variability: Operator technique and coverage affect reproducibility.
• Residues and compatibility: Chemical agents can leave residues and interact with materials or sensitive equipment.
• Workforce exposure: Frequent chemical use increases ergonomic and safety burdens.
• Global standardisation: Replicating efficacy across sites, surfaces, and diverse microbial flora is complex.
AstraZeneca sought a validated, autonomous solution that could complement chemical disinfection, reduce manual burden, and improve consistency and data integrity—while meeting stringent regulatory expectations.
Innovation Description
• Technology: An autonomous robot delivering 254 nm UV C via an eight-lamp tower with reflectors, controlled remotely to eliminate occupational exposure during dosing.
• Digital dosing and verification: Real-time dose monitoring using UVKEY® dosimeter and ILT2400® light meter; webcam-enabled remote oversight; standardized distance (2 m) and vertical coupon orientation for dose uniformity.
• Regulatory-aligned methodology: Surface Challenge Test design based on EN 13697 and acceptance criteria from USP <1072> (≥3 log kill for vegetative organisms; ≥2 log kill for spores/fungi).
• Challenge panel and surfaces: Inclusion of five ATCC strains and key AstraZeneca environmental isolates representing global sites and difficult-to-kill organisms (e.g., UV resistant Micrococcus luteus, objectionable Bacillus cereus, and resilient moulds). Surfaces: stainless steel, glass, vinyl.
• Global applicability: A qualification programme designed to avoid site-by-site requalification through robust organism selection, material coverage, and dose-response curves.
Results
• Routine efficacy at 100 mJ/cm²:
o Vegetative organisms (Staphylococcus aureus, Pseudomonas paraeruginosa, Moraxella osloensis, Candida albicans) achieved ≥3 log reduction across surfaces.
o Micrococcus luteus achieved 2.8–3.0 log reduction, consistent with known UV resistance, meeting acceptance on steel/glass and borderline on vinyl.
• Spore efficacy requires elevated doses:
o Bacillus spizizenii and Bacillus cereus: ≈200 mJ/cm² for 2 log across surfaces (vinyl more demanding).
o Aspergillus brasiliensis and Penicillium chrysogenum: 200–500 mJ/cm² to reach consistent 2 log.
• Surface insights: Stainless steel showed a modest advantage over vinyl and glass for spores; vegetative kill was broadly consistent across materials.
• Controls confirmed robustness: Negative controls were sterile; positive controls achieved target inocula for reliable log calculations.
Impact on Manufacturing
• Quality and compliance: Demonstrates an evidence-based, standards-aligned disinfection modality, reinforcing GMP readiness and audit defensibility with organism-specific death curves and traceable dose verification. In conjunction with UVC lighting we have seen >40% reduction in environmental alert failures in some areas.
• Operational excellence:
o Consistency: Automated, repeatable dosing reduces operator variability.
o Speed and flexibility: Rapid, programmable cycles support routine cleaning and incident response.
• Safety and sustainability:
o Reduced chemical usage and exposure: Less manual spraying and wiping lowers ergonomic strain and VOC/contact risks.
o Residue-free: UV C eliminates concerns of chemical residues on critical equipment.
o Environmental benefits: Potential reductions in solvent/disinfectant consumption and waste streams. Less autoclave cycles for cleaning equipment. Less sterile gowns and single use cleaning wipes.
Global Scalability
• Unified qualification model: A single, robust dataset supports implementation across AstraZeneca sites without redundant requalification, reducing validation overheads and accelerating deployment.
• Data-driven governance: Post-implementation environmental monitoring and trending will quantify bioburden reductions and refine escalation triggers.
Conclusion
The programme delivered a validated, autonomous UV C disinfection capability tailored to pharmaceutical clean rooms, elevating hygienic control, operator safety, and environmental sustainability. By combining rigorous standards-based validation with practical deployment guidance, AstraZeneca advances manufacturing innovation—transforming disinfection from manual routine to a digitally verifiable, globally scalable process. The robot is now in place in 4 facilities with more in progress.
The efficacy data was published in the European Journal of Parenteral and Pharmaceutical Sciences to aid other pharmaceutical companies in adapting this project and to build regulatory acceptance. https://doi.org/10.37521/ejpps30307. The team have also presented the study data at PDA Europe, PDA Ireland and The Aseptic Biopharmaceuticals conference. The paper includes much more detail on the innovative study design and results.
